The beta-3 adrenergic receptor (β3-AR) is by far the least studied isotype of the beta-
adrenergic sub-family. Despite its study being long hampered by the lack of suitable animal …

Haemangioma is a vascular tumour of infancy that is well known for its rapid growth during
the first weeks to months of a child's life, followed by a spontaneous but slow involution …

Currently, propranolol is the preferred treatment for problematic proliferating infantile
haemangiomas (IHs). The rapid action of propranolol has been shown to be especially …

Background Angiosarcomas are rare malignant tumors of vascular origin that represent a
genuine therapeutic challenge. Recently, the combination of metronomic chemotherapy and …

Based largely on retrospective analyses and a handful of prospective case reports,
pharmacological inhibition of the beta adrenergic receptors using beta blockers has shown …

Infantile hemangioma (IH) is a common benign tumor, which mostly resolves spontaneously;
however, children with high-risk IH need treatment. Currently, the recognized first-line …

Propranolol (PRO) is a well-known and widely used non-selective beta-adrenergic receptor
antagonist (beta-blocker), with a range of actions which are of interest in an oncological …

Stress has an emerging role in cancer and targeting stress-related β-adrenergic receptors
(AR) has been proposed as a potential therapeutic approach in melanoma. Here we report …

Infantile hemangioma (IH), which is the most common tumor in infants, is a benign vascular
neoplasm resulting from the abnormal proliferation of endothelial cells and pericytes. For …

Therapeutic targeting of the beta-adrenergic receptors has recently shown remarkable
efficacy in the treatment of benign vascular tumors such as infantile hemangiomas. As …